Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double blind, parallel, multicenter study assessing efficacy and safety of NA- 831 in Subjects with Early Onset of Alzheimer's Disease

Next Previous
Search
Trial Profile

A Phase 3, Double blind, parallel, multicenter study assessing efficacy and safety of NA- 831 in Subjects with Early Onset of Alzheimer's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Traneurocin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 18 May 2023 According to a Biomed Industries media release, protocol for this trial were presented at the Alzheimer's Association International Conference 2022.
    • 12 Sep 2022 New trial record
    • 04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top